Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 4/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.55 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.55 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207605 | 1.00 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14607897 | 0.87 | HPGD (0.57) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL3331311 | 0.83 | HPGD (0.60) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5856133 | 0.82 | HPGD (0.58) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4530460 | 0.81 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7976400 | 0.81 | KCNA3 (0.76) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL5158992 | 0.81 | KCNA3 (0.76) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL5709362 | 0.80 | NPC1 (0.67) | NPC1RAB9AKMT2ASMN1; SMN2TP53 | |
| SCHEMBL2481230 | 0.80 | NPC1 (0.67) | NPC1RAB9AKMT2ASMN1; SMN2TP53 | |
| SCHEMBL2208134 | 0.80 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2TP53BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487798-A4 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916830-B2 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1487798-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-10-14 | — | — | US | disclosed |
| US-6777422-B2 | FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NEUROGEN CORP. | 2004-08-17 | — | — | US | disclosed |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| WO-2003082828-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | C5AR1, C3AR1, C5AR2 | NPC1 2523/4885RAB9A 1068/4885MEN1 1584/4885 |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | C5AR1, C3AR1, C5AR2 | NPC1 2062/4885RAB9A 2127/4885MEN1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.